A massive study found that coronavirus patients who took the malaria drug touted by Trump had a higher risk of death

lramsey@businessinsider.com (Lydia Ramsey)
·3 min read
  • A massive study of 96,032 hospitalized coronavirus patients found that the antimalarial medications hydroxychloroquine and chloroquine did not appear to benefit the patients who took them.

  • Instead, those who received one of the medications had a higher risk of death than those who did not take them.

  • The retrospective study looked at patients over four months across six continents and found that taking the medications was associated with an increased frequency of abnormal heartbeats.

  • Hydroxychloroquine and chloroquine got attention early in the pandemic as a potential treatment for COVID-19, the disease caused by the novel coronavirus. The drugs are approved for other uses but not for the treatment of COVID-19.

  • Visit Business Insider's homepage for more stories.

FILE PHOTO: U.S. President Donald Trump holds a meeting on "opportunity zones" in the Cabinet Room of the White House in Washington, U.S., May 18, 2020. REUTERS/Leah Millis/File Photo
President Donald Trump.

Reuters

We just got even more evidence that the antimalarial medications touted by President Donald Trump aren't a good bet for treating the coronavirus.

A massive new study found that the treatments didn't appear to help patients hospitalized with the novel coronavirus and instead were associated with heart complications and an increased risk of death.

Related: What Could Be the Fastest Way to End the COVID-19 Crisis?

The analysis looked at the hospital outcomes of 96,032 hospitalized patients, 14,888 of whom got some form of the antimalarial treatments chloroquine and hydroxychloroquine over the course of four months.

The patients came from 671 hospitals from six continents, and the study was led by researchers at the Brigham and Women's Hospital in Boston. It was published Friday in the journal Lancet. Though it was not a randomized controlled trial, it's the largest study of its kind in patients with COVID-19, the disease caused by the novel coronavirus.

Never miss out on healthcare news. Subscribe to Dispensed, Business Insider's weekly newsletter on pharma, biotech, and healthcare.

It examined the outcomes of patients who were treated with hydroxychloroquine, hydroxychloroquine and a macrolide antibiotic, chloroquine, or chloroquine and a macrolide antibiotic. Macrolides are a type of antibiotic that includes azithromycin.

Ultimately the authors couldn't find a benefit in those who were given the treatments compared with those who didn't receive any of the combinations. Instead, the study found an increased frequency in abnormal heartbeats in those who received the medications. Those who received the medications had a higher risk of death compared with those who did not take the medications.

To be sure, there are limits to the analysis. It was observational in nature, though randomized controlled trials — which preemptively assign patients either to the medication or a placebo control at random — are underway.

Read more: Here's how 13 top drugmakers are sprinting to develop a coronavirus vaccine or treatment that can halt this pandemic

hydroxychloroquine
Dr. Robin Armstrong with a bottle of hydroxychloroquine.

AP Photo/David J. Phillip

Early in the pandemic, the drug caught the eyes of doctors, experts, and the Trump administration as a potential coronavirus treatment. Some early, promising results regarding the drug were published in late March.

President Donald Trump on Monday said he had been taking hydroxychloroquine every day for a week and a half.

Additional studies, however, have cast doubt on how effective the drug might be in treating the novel coronavirus. A clinical trial taking place in Brazil was halted in April after a spike in deaths among patients who had received the drug.

The drug has not been approved by the US Food and Drug Administration for the treatment of COVID-19.

Two observational studies, published in the New England Journal of Medicine and the Journal of the American Medical Association, found that among thousands of hospitalized coronavirus patients, those who received the antimalarial medication hydroxychloroquine didn't fare better or worse than patients who didn't receive the drug.

Read more: Morgan Stanley analyzed every potential coronavirus vaccine to create a list of the 6 most promising shots that will be ready first

Business Insider